eprex 3000 i.e./0,3 ml raztopina za injiciranje v napolnjenih injekcijskih brizgah
johnson & johnson d.o.o. - epoetin alfa - raztopina za injiciranje - epoetin alfa 3000 i.e. / 0,3 ml - eritropoetin
eprex 4000 i.e./0,4 ml raztopina za injiciranje v napolnjenih injekcijskih brizgah
johnson & johnson d.o.o. - epoetin alfa - raztopina za injiciranje - epoetin alfa 4000 i.e. / 0,4 ml - eritropoetin
eprex 1000 i.e./0,5 ml raztopina za injiciranje v napolnjenih injekcijskih brizgah
johnson & johnson d.o.o. - epoetin alfa - raztopina za injiciranje - epoetin alfa 1000 i.e. / 0,5 ml - eritropoetin
eprex 10.000 i.e./1,0 ml raztopina za injiciranje v napolnjenih injekcijskih brizgah
johnson & johnson d.o.o. - epoetin alfa - raztopina za injiciranje - epoetin alfa 10000 i.e. / 1 ml - eritropoetin
eprex 2000 i.e./0,5 ml raztopina za injiciranje v napolnjenih injekcijskih brizgah
johnson & johnson d.o.o. - epoetin alfa - raztopina za injiciranje - epoetin alfa 2000 i.e. / 0,5 ml - eritropoetin
eprex 20.000 i.e./0,5 ml raztopina za injiciranje v napolnjenih injekcijskih brizgah
johnson & johnson d.o.o. - epoetin alfa - raztopina za injiciranje - epoetin alfa 20000 i.e. / 0,5 ml - eritropoetin
mircera
roche registration gmbh - metoksi polietilen glikol-epoetin beta - anemia; kidney failure, chronic - antianemični preparati - treatment of symptomatic anaemia associated with chronic kidney disease (ckd) in adult patients (see section 5. treatment of symptomatic anaemia associated with chronic kidney disease (ckd) in paediatric patients from 3 months to less than 18 years of age who are converting from another erythropoiesis stimulating agent (esa) after their haemoglobin level was stabilised with the previous esa (see section 5.
vipidia
takeda pharma a/s - alogliptin - diabetes mellitus, tip 2 - drugs used in diabetes, dipeptidyl peptidase 4 (dpp-4) inhibitors - vipidia je navedeno pri odraslih, starih 18 let in starejši s sladkorno boleznijo tipa 2 za izboljšanje nadzora glycaemic v kombinaciji z drugimi glukoze, zniževanje zdravila, vključno z insulinom, ko ti, skupaj z dieto in telesno vadbo, ne zagotavljajo ustrezne glycaemic nadzor (glej točki 4. 4, 4. 5 in 5. 1 za razpoložljive podatke o različnih kombinacijah).
aspaveli
swedish orphan biovitrum ab (publ) - pegcetacoplan - hemoglobinurija, paroksizmal - imunosupresivi - aspaveli is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh) who are anaemic after treatment with a c5 inhibitor for at least 3 months.
bekemv
amgen technology (ireland) uc - eculizumab - hemoglobinurija, paroksizmal - imunosupresivi - bekemv is indicated in adults and children for the treatment of paroxysmal nocturnal haemoglobinuria (pnh). dokazila o kliničnih koristi je dokazana pri bolnikih z haemolysis z klinični simptom(i) okvirni visoke aktivnosti bolezni, ne glede na to, transfuzijo zgodovine (glej poglavje 5.